Experience with transdermal testosterone replacement therapy for hypogonadal men

Susan Parker and Mary Armitage
Diabetes and Endocrine Unit, Royal Bournemouth Hospital, Bournemouth, UK

(Received 27 April 1998; returned for revision 29 May 1998; finally revised 26 June 1998; accepted 4 August 1998)

Summary

BACKGROUND None of the existing options for long-term testosterone replacement therapy (TRT) for hypogonadal men are ideal. Depot replacement at frequent intervals and implants are effective but invasive and inconvenient for the patient. Oral therapy results in poor hormone levels. Both are associated with undesirable metabolic changes. A transdermal formulation therefore represents a potential therapeutic advance for testosterone replacement.

OBJECTIVE To carry out a clinical audit of the acceptability and efficacy as a treatment for hypogonadism of the first transdermal testosterone therapy available in the UK (Andropatch, SmithKline Beecham) compared with existing androgen replacement options.

PATIENTS AND MEASUREMENTS Serum testosterone and questionnaire data on treatment efficacy, side-effects, therapy preference, sexual dysfunction and partner’s attitudes to therapy were obtained from 50 hypogonadal men prescribed long-term testosterone replacement.

RESULTS Eighty per cent of the men returned analysable questionnaires. Eighty-four per cent experienced adverse effects with transdermal therapy, most commonly dermatological problems; 22% of the sample elected to continue with transdermal replacement, 72% returned to depot and 5% returned to oral therapy. The reservoir patches were judged to be too large, uncomfortable, visually obtrusive and noisy. Testosterone levels were comparable to those obtained with depot replacement with the added advantage of a more physiological pharmacokinetic profile. Men taking oral preparations were consistently under-replaced.

CONCLUSIONS Adverse events were substantially higher than reported from clinical trials but in keeping with the spectrum of yellow card reports received by the Committee on Safety of Medicines. The pharmacokinetic advantages are thus largely outweighed by low patient acceptability. In its present form transdermal therapy remains an expensive option for those who cannot tolerate depot testosterone replacement.

Hypogonadism is the most common hormone deficiency in men affecting five in every 1000 men of all ages (Wu, 1996). There are currently approximately 34 000 patients receiving testosterone replacement therapy (TRT) in the UK (IMS, 1997); 43% is in the form of intramuscular depot injections at 2- or 3-weekly intervals, 24% oral replacement, 23% implants and 10% transdermal. All treatment modalities have disadvantages. Oral TRT has poor bioavailability even with frequent daily dosing. Intramuscular injections are inconvenient, uncomfortable and result in widely fluctuating levels of testosterone and its metabolites (dihydroxytestosterone and oestradiol) over the dosing interval. Implants produce well-sustained testosterone levels but involve a minor surgical procedure and risk of extrusion, infection or scarring. They are not offered widely outside urology clinics. Endocrinologists tend to recommend depot replacement, with oral replacement most widely prescribed in general practice. Conventional TRT is associated with a reduction in HDL cholesterol, polycythaemia from increased erythropoesis and changes in insulin sensitivity—all of which raise the cardiovascular risk index. Transdermal therapy (Fig. 1) was introduced into the UK in August 1996 and promised to redress many of these disadvantages. It is designed to deliver normal circulating hormone levels with one or, more usually, two daily patches applied in the evening. This results in the theoretically advantageous delivery of testosterone in a physiological diurnal pattern free of associated metabolic disturbances (Meikle et al., 1996).

However, the reported clinical trials were conducted over relatively small numbers of volunteers. We were keen, therefore, to assess the efficacy and compliance rate in a clinical population. The transdermal route is expensive and we felt we needed to demonstrate clear superiority over other treatment options to justify its recommendation.

Subjects and methods

Hypogonadal men receiving long-term TRT were recruited...
from both the pituitary clinic of the Endocrine Unit at the Royal Bournemouth Hospital and the psychosexual medicine clinic of the East Dorset Healthcare Trust. We wrote to referring GPs sending full details of the new transdermal therapy and invited their co-operation in offering a change of therapy. Fifty consecutive clinic attenders were provided with information about Andropatch and, where both GP and patient consented to a change in therapy, these volunteers were asked to complete a confidential questionnaire and to provide a blood sample for testosterone and SHBG assays after 3 months on therapy, earlier if therapy was interrupted for any reason. LH and FSH were not checked routinely as many of the men were hypophysectomized. Data about pretreatment hormone levels and testosterone levels achieved by previous treatments were obtained (where these existed) by searching clinic case notes and GP medical records. We notified all respondents and their GPs of the outcome of assays with advice about ongoing therapy either by letter or, where appropriate, by clinic follow-up.

A two-page questionnaire was devised by the authors and piloted in this project. It was semistructured with several open-ended questions to allow for a wide spectrum of responses, particularly about the reasons for treatment preferences and problems with all treatment options. Respondents were asked about duration of therapy, previous therapies, problems with therapy, treatment preference, partner’s response to treatment, symptoms of androgen deficiency and treatment efficacy.

Results

Response rate

Forty of the 50 men (80%) agreed to participate and returned completed questionnaires which formed the basis for the analysis. Three GPs were unwilling to prescribe Andropatch and seven men did not respond to our correspondence on two occasions and were then omitted from the project.

Pretreatment

All men had biochemically established hypogonadism with pretreatment testosterone levels between 2 and 6 nmol/l. Gonadotrophins were raised in 24 men with primary hypogonadism but not in 16 men with pituitary dysfunction or hypophysectomy. Table 1 shows diagnoses and Fig. 2 shows the age distribution of the sample.

Duration of therapy

Nine men (24%) had been diagnosed and treated for less than 6 months, 10 (26%) for 6–18 months, 13 (34%) for 19 months–5 years and six (16%) for longer than 5 years.

Previous therapy

Thirty-six men were transferred from depot androgens, seven had previous experience with oral replacement and one man transferred directly from oral to transdermal therapy. All 40

![Fig. 1 Andropatch (SmithKline Beecham).](image1)

![Fig. 2 Age distribution of hypogonadal men.](image2)

men tried Andropatch. Three men were newly diagnosed and started Andropatch as their first replacement regime.

**Duration of therapy with Andropatch**

Thirteen of 40 (32%) continued with transdermal therapy for the full 3 months under review. Three men stopped therapy within 2 weeks due to perceived lack of efficacy (no testosterone levels available); 24/40 (60%) dropped out between 4 and 8 weeks of therapy because of worsening skin reactions. There were no drop-outs between 8 and 12 weeks.

**Ongoing therapy**

Twenty-nine of 40 (72%) returned to depot androgens for ongoing therapy, 9/40 (22%) continued to use transdermal replacement and 2/40 (5%) abandoned all therapy as being unsatisfactory. Eight of the nine men who continued with patches had been transferred from an alternative long-term TRT. One of three newly diagnosed men for whom Andropatch was their first experience of TRT continued with patches.

**Problems with therapy**

Only 16% of men reported they were problem-free with Andropatch compared with 52% problem-free with depot preparations. Tables 2 and 3 show the relative frequency of reported adverse effects. Of the 7/40 men who had tried oral therapy the only complaint was of low replacement levels. Many men commented they would prefer oral therapy.

**Sexual dysfunction**

Twelve of 40 men did not complete any questions about sexual dysfunction. The remaining 28 respondents all reported sexual dysfunction increasing in severity over time (Table 4). Lack of libido was a problem for 42%, ejaculatory changes, most frequently ejaculatory failure for 75%, and all respondents experienced disturbances of erectile dysfunction and consequently in the frequency of sexual intercourse. More than half the respondents reported no improvements in sexual dysfunction after TRT (Table 5). The apparent bias in favour of depot

replacement is difficult to interpret, given the relatively short treatment interval with transdermal therapy.

**Adverse effects**

Two-thirds of respondents found the Andropatch unsatisfactory. Patches were variously described as noisy, visually indiscreet, embarrassing, unpleasant to apply and remove and generally to be socially unacceptable. They fell off in swimming pools and showers, attracted ribald comments from sporting partners and left bald red marks over trunk and limbs. Dogs, wives and children were distracted by noise of the patches with body movements. Those with poor mobility or manual dexterity (and several were over 70 years of age) found it difficult to remove packaging and apply patches dorsally.

The most serious adverse effects related to skin reactions which ranged from mild irritation to persisting rashes, blistering and burns. Most skin reactions developed after 3 weeks and gradually worsened over 4–6 weeks. All tended to persist for days to weeks after removing the patches and were sufficiently noxious to terminate therapy. The authors did not personally see all the skin complaints reported in the questionnaires, most of which were managed by general practitioners. In those men who were followed-up in the endocrine clinic red, macular areas were still visible on legs and trunk in a few cases up to 2 months after termination of transdermal therapy.

One respondent reported the development of a transient, itchy, macular red rash at patch sites when he drank alcohol 6 months after stopping Andropatch.

**Partner’s response to therapy**

Comments ranged from ‘no difference’ to ‘great improvement in husband’s wellbeing’ and tended to refer to androgen replacement in general. Three women thought their partners in husband’s wellbeing’ and tended to refer to androgen replacement but our main interest focused on the patients’ response to a novel TRT. For most men the comparison was between a long-established parenteral therapy and a new therapy. Whatever bias this may have introduced, the main reason for poor compliance with the new therapy was painful skin reactions at the patch sites.

This would have occurred so frequently in those who had no prior experience of parenteral TRT remains to be seen, as only three of our sample were newly diagnosed. None of our respondents had tried testosterone implants and only seven of 40 had tried oral replacement. Nevertheless, we feel our survey is an accurate reflection of clinical practice in that most hypogonadal men are currently receiving parenteral replacement and, although they would prefer transdermal therapy in principle, they will be unable or unwilling to tolerate the skin patch prescribed during this audit.

Andropatch is a large reservoir patch requiring daily application. Like cellophane paper, it is noisy when deformed. Overall it was found to be too conspicuous, audible and uncomfortable for long-term use and the daily rotation of sites was problematical for the high proportion of men who developed skin sensitivity, rashes, burns or itchiness. Three-quarters of our sample expressed a preference for a modified form of transdermal therapy but elected to return to parenteral therapy. Similar problems were encountered with the first transdermal oestrogen patches for women and were overcome.

**Testosterone levels**

All men on two patches and those who had previously had depot testosterone oenanthate 250–500 mg (Primoteston, Schering) were adequately replaced (Fig. 3). The wide range of values recorded for all depot formulations reflects the difference between peak and trough serum testosterone levels. Our preference, in the hospital endocrine clinic, is to measure peak levels mid-dose but monitoring is not standardized among general practitioners. The testosterone levels achieved with transdermal therapy cluster more closely together consistent with a regular daily delivery. Variations in level bore no consistent relationship with skin irritation or hirsutism. The highest level achieved (44·3 nmol) was recorded from a man with severe skin irritation and another patient with widespread ichthyosis had levels of 21·4 nmol. One patient showed us a selection of used patches with varying amounts of gel remaining in the central reservoir, suggesting that anatomical site is the main determinant of absorption rate in some men. The nine men who chose to remain on Andropatch achieved the highest circulating testosterone levels and the least skin irritation. Only one was newly diagnosed and had no previous experience of other TRT. Depot mixed testosterone esters (Sustanon 250, Organon) delivered a much lower range of levels roughly equivalent to oral replacement with testosterone undecanoate 160 mg (Restandol, Organon) or a single testosterone patch.

**Discussion**

The aim of this audit exercise was to acquire sufficient experience with a new therapy to enable us to respond to queries from GPs and patients and to form a rational basis for our own prescribing practise. Hormone assays confirmed the adequacy of androgen replacement but our main interest focused on the patients’ response to a novel TRT. For most men the comparison was between a long-established parenteral therapy and a new therapy. Whatever bias this may have introduced, the main reason for poor compliance with the new therapy was painful skin reactions at the patch sites.

Whether this would have occurred so frequently in those who had no prior experience of parenteral TRT remains to be seen, as only three of our sample were newly diagnosed. None of our respondents had tried testosterone implants and only seven of 40 had tried oral replacement. Nevertheless, we feel our survey is an accurate reflection of clinical practice in that most hypogonadal men are currently receiving parenteral replacement and, although they would prefer transdermal therapy in principle, they will be unable or unwilling to tolerate the skin patch prescribed during this audit.
by developing the technologically superior matrix delivery system (Ross et al., 1997). Compared with the small matrix patches now available for oestrogen and progesterone replacement in women Andropatch is a disappointing development.

The incidence of skin reactions sufficiently noxious to interrupt therapy (52%) was higher than that reported from clinical trials in which only 9·8% discontinued treatment. The skin reactions varied in severity, but were a very significant deterrent to compliance. Of 39 yellow cards received to date (9/6/97) by the CSM, 34 adverse events related to skin reactions (ADROIT et al. 1997). Overall usage is still low, so this is clearly the major disadvantage of therapy. Once skin reactions had occurred they persisted over time, gradually becoming worse. The magnitude of the problem had not been anticipated at the outset of our audit so we did not recommend the use of prophylactic skin treatments. More recently it has been suggested that the skin eruptions may be responsive to hydrocortisone cream 1% or triamcinolone, but our own experience is too limited to comment.

Good levels of testosterone replacement are achieved and compare favourably with depot testosterone oenanthate (Primo-teston). Depot mixed testosterone esters (Sustanon) has a lower bioavailability but is still superior to oral replacement, which consistently produced low plasma testosterone (<6 nmol/l), and as such cannot be recommended for men with genuine hypogonadism.

Conclusions

Transdermal therapy has much to recommend it if the technical problems can be overcome. Its superior pharmacokinetic profile, convenience and the accuracy with which therapy can be monitored by plasma assays are all major advantages. In its present formulation it is unlikely to make a major contribution to testosterone replacement therapy because of its adverse skin reaction profile and low patient acceptability. It remains an option, perhaps, for newly diagnosed hypogonadal men. Good levels of testosterone replacement are achieved and compare favourably with depot testosterone oenanthate (Primo-teston). Depot mixed testosterone esters (Sustanon) has a lower bioavailability but is still superior to oral replacement, which consistently produced low plasma testosterone (<6 nmol/l), and as such cannot be recommended for men with genuine hypogonadism.

Acknowledgements

We thank SmithKline Beecham for their financial support of this audit.

References


Appendix

Self-report of Testosterone Replacement Therapy (TRT)

Confidentiality

The questions in this survey are very personal. Your answers will be treated in strict confidence. Please do NOT put your name on the survey. It will be identified by your personal number in the box at the top of the pages. When you have finished it send it back to us in the enclosed stamped addressed envelope.

Importance

Please take your time and give us as much information as you can. We will be using your opinions and experience to evaluate the new testosterone patch and compare it with other types of TRT. We will let you have your own blood test results and also a summary of the outcome when the survey is completed.

SECTION 1: TRT

1. How long ago did you first start to use testosterone therapy?

2. What was the reason for having testosterone therapy?

3. Please tick which of the following treatments you used before trying patches:

   Name
   Dose:
   How often:
   Sustanon
   Primoteston
   Restandol
   Other (name)

© 1999 Blackwell Science Ltd, Clinical Endocrinology, 50, 57–62
* injections
* tablets

5. Did you experience any problems or side effects with this treatment?

6. How long have you been using testosterone patch therapy?

7. Did you have any problems or side effects with the patches?

8. Which treatment did you prefer?

9. Which treatment will you be staying on in future?

10. Do you have a partner? Yes/No If yes, what does your partner think about TRT?

11. Please use this space to add any further comments, suggestions or criticisms:

**SECTION 2: Before Testosterone Therapy**

1. Before you had testosterone replacement did you have any of the following problems? Please tick any which happened to you:
   - Loss of interest in sex
   - Faster ejaculation than usual
   - Slower ejaculation than usual
   - Inability to ejaculate
   - Fewer spontaneous erections (e.g. on awakening)
   - Complete loss of spontaneous erections
   - Partial loss of erections during sex
   - Complete loss of all erections
   - Decreased frequency of sexual intercourse
   - No sexual intercourse

2. Had you noticed any change in your moods? Yes/No

   If Yes, please describe: 

   3. Had you noticed any changes in muscle bulk or strength? Yes/No If Yes, please describe:

   4. Did you have any other health problems you think were related to low testosterone levels?

   **SECTION 3: Effects of Therapy**

   In this section we would like you to comment on the effectiveness of your testosterone therapy. Please circle the answer which best describes your own response to treatment with either testosterone injections or patches.

   1. Sexual interest was
      - increased
      - decreased
      - unchanged (injections)

   2. Ejaculation was
      - faster
      - slower
      - unchanged (injections)

   3. Spontaneous erections
      - increased
      - decreased
      - no change (injections)

   4. Strength of erections
      - increased
      - decreased
      - unchanged (injections)

   5. Duration of erections
      - increased
      - decreased
      - unchanged (injections)

   6. Loss of erections
      - improved
      - normal again
      - unchanged (injections)

   Thank you for your help.

© 1999 Blackwell Science Ltd, Clinical Endocrinology, 50, 57–62